Literature DB >> 6410234

Acid-labile alpha interferon. A possible preclinical marker for the acquired immunodeficiency syndrome in hemophilia.

M E Eyster, J J Goedert, M C Poon, O T Preble.   

Abstract

Many homosexual men with the acquired immunodeficiency syndrome (AIDS) have an unusual acid-labile form of human leukocyte, or alpha, interferon in their serum. Male patients with classic hemophilia treated with lyophilized clotting-factor concentrates are also at high risk for the development of AIDS. To determine whether the level of alpha interferon may be a preclinical marker of early subclinical disease, we examined stored plasma and serum from three hemophilic patients with AIDS. Persistently elevated levels of the acid-labile form of alpha interferon were found in all three patients. In two patients the appearance of circulating alpha interferon preceded the onset of clinical disease by 3 to 10 months. In contrast, alpha-interferon levels were not elevated in 43 of 46 unselected patients with hemophilia; three of these patients had transient elevations. These results suggest that acid-labile alpha interferon may be a marker that can be used to identify affected asymptomatic members of high-risk groups before the onset of clinical disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6410234     DOI: 10.1056/NEJM198309083091003

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  38 in total

1.  Evidence against an autoimmune aetiology for inflammatory bowel diseases.

Authors:  F Pallone; S Fais; M R Capobianchi
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

2.  Spontaneous release of interferon as a predictor of clinical evolution in HIV-positive subjects.

Authors:  A Biglino; A Surbone; F Lipani; N Cappello; B Forno; A M Pollono; M Busso; A Pugliese
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

Review 3.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

4.  Intracellular staining of Mx proteins in cells from peripheral blood, bone marrow and skin.

Authors:  A N al-Masri; T Werfel; D Jakschies; P von Wussow
Journal:  Mol Pathol       Date:  1997-02

5.  Association of alpha interferon production with natural killer cell lysis of U937 cells infected with human immunodeficiency virus.

Authors:  G Rappocciolo; J F Toso; D J Torpey; P Gupta; C R Rinaldo
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

Review 6.  Interferons, a group of multiple lymphokines.

Authors:  H Kirchner
Journal:  Springer Semin Immunopathol       Date:  1984

7.  Presence of interferon and anti-interferon in patients with systemic lupus erythematosus.

Authors:  P von Wussow; D Jakschies; K Hartung; H Deicher
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

8.  Induction of alpha interferon by human immunodeficiency virus type 1 in human monocyte-macrophage cultures.

Authors:  J Szebeni; C Dieffenbach; S M Wahl; C N Venkateshan; A Yeh; M Popovic; S Gartner; L M Wahl; M Peterfy; R M Friedman
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

9.  Absence of circulating interferon in patients with inflammatory bowel disease. Suggestion against an autoimmune etiology.

Authors:  M R Capobianchi; S Fais; M C Di Paolo; D Agostini; P Paoluzi; F Pallone; F Dianzani
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

10.  Selective decrease in human immunodeficiency virus type 1 (HIV-1)-induced alpha interferon production by peripheral blood mononuclear cells during HIV-1 infection.

Authors:  J Ferbas; J Navratil; A Logar; C Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  1995-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.